Category: Commercialization Agreement
Shots: Wanchunbulin to receive $30M up front, $170M as regulatory and sales milestone & is eligible to receive $15M as equity investment at a pre-money valuation of $560M Hengrui gets exclusive rights to commercialize & co-develop plinabulin in Greater China and will be accountable for all costs associated with the commercialization of plinabulin in the […]
Shots: The companies collaborated to commercialize the first biosimilar Darbepoetin alpha in the GCC market for the treatment of anemia associated with chronic renal failure. The CKD biosimilar is currently approved in South Korea The collaboration with CKD helps to build the biosimilar footprint in the Middle East and Africa markets to reach more people […]
The German pharmaceutical company Dr. August Wolff GmbH & Co. KG Arzneimittel Arzneimittel (“Dr. Wolff”) and the Spanish pharmaceutical company Cantabria Labs (“Cantabria Labs”) concluded a strategic partnership on March 12th 2021 by entering into an exclusive licensing agreement for a newly developed medicinal product for the treatment of hyperhidrosis. Under the terms of the […]
Shots: Bio-Thera to receive $30M up front following the achievement of P-III satisfactory results and is eligible for commercial milestones along with royalties. The transaction is expected to close in Q2’21 Biogen to get exclusive regulatory, manufacturing, and commercial rights of BAT1806 in all countries excluding China (includes Hong Kong, Macau, and Taiwan) Biogen will […]